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Introduction
CD69 is a leukocyte receptor transiently induced after
activation (1–5) that is detected on small subsets of T
and B cells in peripheral lymphoid tissues from healthy
subjects (6). In addition, CD69 is persistently expressed
in leukocyte infiltrates of various chronic inflammato-
ry diseases (7, 8). Several reports have indicated that
CD69 is involved in the in vitro activation of bone mar-
row–derived cells (2, 3, 9). Nevertheless, the functional
role of this molecule could be different in vivo. Trans-
genic CD69 mice accumulate mature thymocytes at the
medulla of the thymus (10, 11). In this regard, we have
found that hematopoietic cell development, thymocyte
positive and negative selection, and T cell maturation
is normal in CD69–/– mice under physiological condi-
tions (12). In addition, NK cell–dependent tumor rejec-
tion is favored in the absence of CD69 (13). However,
the functional role of CD69 expressed by T cells and
macrophages at inflammatory sites and in autoim-
mune processes has not been explored.
Murine collagen-induced arthritis (CIA) is a T
cell–dependent, antibody-mediated autoimmune dis-
ease directed against cartilage type II collagen (CII) (14).
CIA is a widely accepted experimental model of inflam-
matory joint disease, mainly rheumatoid arthritis (RA)
(14). A strong inflammatory cell infiltrate with prolif-
eration of synovial cell lining (pannus) as well as carti-
lage and bone destruction are seen in CIA and RA. In
addition, proinflammatory cytokines (IL-1β, TNF-α)
and various chemokines are involved in the pathogen-
esis of the immune-mediated joint damage observed in
CIA and RA (15). TGF-β1 is considered an anti-inflam-
matory cytokine, and null mutations of the TGF-β1
gene result in a severe multiorgan inflammatory disor-
der that is rapidly lethal (16, 17). TGF-β1 downregu-
lates proinflammatory cytokine production (18, 19)
and exerts a clear-cut protective effect on CIA (20, 21).
However, intra-articular injection of high amounts of
this cytokine also induces synovitis and fibroblast
hyperplasia (22), and systemic administration may be
deleterious (23). The balance between proinflammato-
ry and anti-inflammatory cytokines is thus crucial to
the outcome of the disease (15). Therefore, tissue levels
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of TGF-β have a critical role in inflammation, and the
molecules involved in its modulation are interesting
potential therapeutic targets.
To ascertain the functional in vivo role of CD69 in
autoimmune reactivity and inflammation, we analyzed
the behavior of CIA in CD69-deficient B6 mice. An exac-
erbated form of CIA was observed in CD69–/– mice that
correlated with higher CII-specific T and B cell respons-
es, an increase in some inflammatory mediators, and
diminished local TGF-β synthesis. Local blockade of
TGF-β increased CIA severity in WT but not in CD69-
deficient mice. In addition, in vitro engagement of
CD69 induced the production of TGF-β1. These results
strongly suggest that CD69 is a negative regulator of
autoimmune reactivity through TGF-β synthesis.
Methods
Mice. Mice were bred at the Centro Nacional de Biotec-
nologia (Madrid, Spain) under specific pathogen–free
conditions. All experiments were performed using mice
on a C57BL/6 genetic background. CD69–/– mice were
backcrossed on C57BL/6 background 12 times. WT
and CD69–/– mice used for experiments were litter-
mates or age-matched litters whose parents were litter-
mates and were 6–13 weeks of age at the time of exper-
imentation. All procedures involving animals and their
care were approved by the Ethics Committee of the
University of Madrid and were conducted according to
institutional guidelines that are in compliance with the
National Institutes of Health’s Guide for the Care and Use
of Laboratory Animals.
Induction and assessment of CIA. CFA was prepared by
mixing 100 mg of heat-killed M. tuberculosis (H37Ra,
Difco, Detroit, Michigan, USA) with 20 ml of incomplete
Freund’s adjuvant (Sigma-Aldrich, St. Louis, Missouri,
USA). Chick CII (Sigma-Aldrich, 2 mg/ml) was dissolved
overnight at 4°C in 10 mM acetic acid and combined
with an equal volume of CFA. Mice were injected intra-
dermally at the base of the tail and boosted at days 21
and 38, following a modified protocol (24). Control mice
were treated with CFA without CII. The severity of arthri-
tis was monitored by direct examination with a digital
caliper according to the following scale: grade 0, no
swelling; 1, slight swelling and erythema; 2, pronounced
inflammation; and 3, joint rigidity. Each limb was grad-
ed, giving a maximum possible score of 12 per animal.
Paws to be histologically analyzed were chosen before
the experiment. After sacrifice, paws were collected,
fixed, decalcified, and paraffin embedded. Sections (5
µm) were stained with hematoxylin and eosin and
scored according to the following scale: 0, no inflam-
mation; 1, slight thickening of synovial cell layer and/or
some inflammatory cells in the sublining; 2, thicken-
ing of synovial lining, infiltration of the sublining, and
localized cartilage erosions; and 3, infiltration in the
synovial space, pannus formation, cartilage destruc-
tion, and bone erosion.
Cell proliferation assays. Draining LN and spleen cells 
(2 × 105) in 200 µl of RPMI medium (containing 50
µM 2-ME and 10% FCS) were cultured in triplicate in
a 96-well plate at 37°C (5% CO2) for 72 hours with
0–50 µg/ml of denatured CII (boiled for 10 minutes).
Cells were pulsed with 1 µCi per well of [methyl-3H]
thymidine ([3H]TdR) (Amersham, Little Chalfont,
United Kingdom) for the last 12 hours of culture
before harvesting onto glass fiber filters for determi-
nation of [3H]TdR uptake.
Detection of anti-CII antibodies. ELISA for antibody to CII
was performed as previously described (25). HRP-conju-
gated secondary antibody specific for IgG1, IgG2a,
IgG2b, IgG3, or IgM (Southern Biotechnology, Birming-
ham, Alabama, USA) and IgA (Sigma-Aldrich) were used.
Cell isolation. Positive selection of splenocyte subsets
was performed using specific biotin-conjugated anti-
bodies against CD11b, CD3, CD4, and CD8, all from
BD-Pharmingen (San Diego, California, USA), and
biotin binder Dynabeads (Dynal A.S., Oslo, Norway)
yielding about 98% cell purity. Mouse synovial cells
were isolated from CIA WT mice as described for
human synovial tissue (26), and further subset purifi-
cation was performed as shown above. After positive
selection of CD11b+ and CD3+ synovial cells, synovial
cells were incubated with biotin CD45 and negatively
selected using excess of avidin-magnetic beads. The
remaining CD45-negative cells were used for RNA
extraction. Synovial fluid leukocytes were obtained
from synovial effusions drained from the inflamed
knees of patients with reactive arthritis, ankylosing
spondylitis, and RA who fulfilled the American College
of Rheumatology 1987 criteria (27) and were purified
by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) den-
sity-gradient centrifugation.
RNase protection assay and quantitative real-time RT-PCR
analyses. Joints were homogenized with a Polytron
(Kinematica, Littau, Switzerland), and total RNA was
isolated using the Ultraspec RNA reagent (Biotecx,
Houston, Texas, USA). RNase protection assays were
performed on 2.5–5 µg of RNA using the Riboquant
MultiProbe RNase Protection Assay System (Phar-
Mingen, San Diego, California, USA) according to the
manufacturer’s instructions. For RT-PCR, 2 µg of
DNaseI-treated RNA were reverse transcribed with
MuLV RT (Roche Diagnostics Ltd., Lewes, United
Kingdom). Real-time PCR was performed in a Light-
cycler rapid thermal cycler system (Roche, Mannheim,
Germany) using primers from various exons that gen-
erated products about 200 bp in length. Results for
each cytokine are normalized to GAPDH expression
and measured in parallel in each sample.
Antibodies. Murine mAb specific for mouse CD69 was
generated by fusion of NS-1 myeloma cells with spleno-
cytes from a CD69–/– mouse immunized with mouse
pre-B cells expressing CD69 (13). Antibodies specific
for CD69 were purified and used in in vitro cytokine
production assays. Mouse anti-human TP1/8 mAb has
been described previously (3).
The blocking anti–TGF-β 1D11.16.8 (mouse IgG1
hybridoma, purchased from ATCC, Manassas, Virginia,
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USA) (28) at 2 mg/ml in 25 µl of PBS, PBS only, or an
irrelevant control isotype-matched mAb were injected
subcutaneously in one of the hind paws every 2 days
after the second injection of CII (day 21), and paw
inflammation was monitored.
Determination of cytokine production. To determine the
levels of cytokines in washouts of joint tissue, patellas
with adjacent synovium were obtained at sacrifice of
the mice (day 50), in a standardized manner from knee
joints as previously described (29), and incubated in
RPMI-1640 medium (200 µl per patella) with 0.1% BSA
for 1 hour at room temperature. Then, active and total
TGF-β1 (Emax ImmunoAssay System, Promega Corp.,
Madison, Wisconsin, USA) and IL-1β, TNF-α, and
RANTES (OptEIA ELISA Sets, BD-Pharmingen) were
quantified in culture supernatants.
For in vitro cytokine production, mouse splenocytes
(prestimulated with 5 µg/ml Concanavalin A [ConA;
Sigma-Aldrich] for 16 hours and then purified as
described above) or synovial cells were incubated with an
anti-mouse CD69, clone CD69.2.2 (mouse IgG1), or con-
trol mouse IgG1 mAb (both at 10 µg/ml) plus a goat
anti-mouse IgG Fc fragment–specific F(ab′)2 (Jackson
Immunoresearch, West Grove, Pennsylvania, USA) at 20
µg/ml. Then, active and total TGF-β1, IL-1β, TNF-α, and
RANTES were assayed in culture supernatants after 24
Figure 1
Exacerbated CIA in CD69–/–
mice. (a) CFA-treated control
mice (left panels) are com-
pared with representative pic-
tures of the most severe cases
of CIA in CD69+/+ mice and
CD69–/–mice (middle and right
panels, respectively). (b) Inci-
dence of arthritis (percentage
of diseased mice) and severity
of clinical signs in CD69+/+ (cir-
cles), CD69+/– (triangles), and
CD69–/– (squares) mice evalu-
ated as described in Methods.
Results correspond to the
arithmetic mean ± SD from
three separate experiments (18
mice per group per experiment).
*P < 0.01 versus CD69+/+
(Student’s t test).
Figure 2
Histological assessment of CIA in CD69-deficient mice. (a) Representative section of joint histopathology on whole paws of control (CFA,
left panel, ×100) and CII-immunized CD69+/+ (middle panel, ×100) and CD69–/– (right panel, ×60) mice. Arrowheads indicate cartilage and
bone erosions, and arrows indicate leukocyte infiltrates and pannus. C, cartilage; B, bone. (b) Scoring of inflammation, cartilage damage,
pannus formation, and bone erosion of paws from CD69+/+ (white bars) and CD69–/– (black bars) mice as described in Methods. Results
are expressed as the arithmetic mean ± SD of the percentage of joints ascribed to each severity group from three independent experiments
(eight mice per group per experiment); *P < 0.01 versus CD69+/+ (Mann-Whitney U test).
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hours, as above. For cytokine production by human cells,
we used human synovial fluid leukocytes from patients
with inflammatory joint diseases, purified as described
above, and stable transfectants of CD69 in the Jurkat
leukemic T cell line, which was previously characterized
(30). Cells were treated at 106 cells per milliliter with the
anti-human CD69 TP1/8 or with an isotype control
mAb, with or without cross-linking. TGF-β1 was assayed
in culture supernatant after 24 hours, as above.
Results
CD69-deficient mice develop an exacerbated form of CIA. To
explore the role of CD69 in a model of chronic autoim-
mune arthritis, we compared interbred B6 WT and
CD69–/– mice (12) for incidence and severity of CIA
induced by intradermal immunization with CII in CFA,
which elicits a moderate arthritis in B6 mice (24).
CD69-deficient mice developed an exacerbated form of
CIA, with severe swelling of the footpad, ankle and
wrist joints, and digits (Figure 1a) and significantly
higher incidence and severity than in WT mice (Figure
1b). Furthermore, CD69+/– mice, which express inter-
mediate levels of CD69 (12), showed a higher incidence
and severity of CIA than WT mice but significantly
lower than CD69–/– mice (Figure 1b).
To further evaluate arthritis, hematoxylin- and
eosin-stained sections of paws from CD69–/– and WT
mice with different grades of CIA were assessed by his-
tological analyses. These studies paralleled the results
shown for clinical evaluation, with a significantly
higher percentage of joints with severe pathology
observed in CD69–/– mice than in WT mice (Figure 2a).
Joints from CD69-deficient mice more frequently
showed widespread infiltration of inflammatory cells,
with pannus tissue extending from the marginal zones
to the cartilage and through the medulla of subchon-
dral bone (Figure 2, a and b). In late-stage disease,
there was destruction of articular cartilage and bone,
with loss of normal joint architecture. Therefore, these
results showed a clear-cut inverse correlation between
CIA severity and expression of CD69, suggesting an in
vivo inhibitory role for CD69 in CIA development.
Figure 3
Enhanced CII-specific immune response in CD69–/– mice. (a) Enlarged spleens of CD69–/– compared with CD69+/+ mice. Scale bar: 1 cm. (b)
Spleen weight and cell number (arithmetic mean ± SD) from CFA control and CII-immunized (CIA) CD69+/+ (white bars) and CD69–/– (black
bars) mice are shown. *P < 0.01 versus WT immunized mice (Student’s t test). (c) Proliferation of spleen and LN cells from CII-immunized
CD69+/+ (white bars) and CD69–/– (black bars) mice stimulated with different concentrations of inactivated CII (x axis). Data correspond to
the arithmetic mean ± SD of [3H]TdR uptake in three independent experiments. *P < 0.01 versus CD69+/+ (Mann-Whitney U test). Sp, spleen.
(d) Increments of CII-specific Th1-dependent isotypes in CD69–/– mice. CII-specific IgG1 and IgG2b (1:20,000 serum dilution), IgG2c and
IgG3 (1:5,000 serum dilution), and IgM and IgA (1:200 serum dilution) antibody levels in sera collected at sacrifice (day 50) of CFA-treat-
ed control or CII-immunized (CIA) CD69+/+ (white bars) and CD69–/– (black bars) mice. Data are represented as the arithmetic mean ± SD
of absorbance units at 495 nm in three separate experiments (10 mice per group per experiment). *P < 0.01 versus CD69+/+ (Student’s t test).
876 The Journal of Clinical Investigation | September 2003 | Volume 112 | Number 6
Enhanced collagen type II-specific immune response in
CD69–/– mice. These results strongly suggested that
CII triggers an exacerbated immune response in
CD69–/– mice. Accordingly, the spleen was signifi-
cantly enlarged in CD69–/– CII-challenged mice
(about 1.4-fold heavier, P < 0.001, t test) as compared
with WT mice at 13 weeks of age, suggesting a high-
er activation of the immune system in arthritic
CD69–/– mice (Figure 3, a and b). The increase in
spleen weight correlated with an increased cellulari-
ty (Figure 3b). Next, we ascertained whether this
increment in cellularity was due to a difference in any
subpopulation of immune cells present in the spleen.
The proportion of T cells, B cells, macrophages, and
NK cells as well as the CD4/CD8 ratio, the
naive/effector-memory cell ratio (CD62L/CD44), and
the proportions of CD45RBlow CD25+ CD4+ regula-
tory T cells were analyzed. The proportion of these
subsets was conserved between WT and CD69–/– mice
either in the absence of any stimulation or after CII
challenge (data not shown).
To assess lymphocyte reactivity, we analyzed the 
CII-specific proliferative response of lymphocytes from
spleen and lymph nodes. Lymphocytes from CD69–/–
mice proliferated to a significantly higher extent than
those from WT mice at the different doses of CII test-
ed (Figure 3c), indicating an inhibitory influence of
CD69 in the CII-specific proliferation of immune cells
from CII-challenged mice.
We next investigated the humoral response to CII.
Analyses of serum concentration of anti-CII isotypes
showed significantly augmented levels of the Th1-
dependent isotypes IgG2c, which is equivalent in B6
mice to IgG2a, and IgG2b (Figure 3d). A significant
increment in IgG3 was also found, indicating B cell
hyperresponsiveness in CD69–/– mice, while the reduc-
tion in IgM would suggest enhanced shift to IgG. The
Th-2–dependent IgG1 was not significantly different,
and CII did not induce a significant IgA response. Alto-
gether, these results suggest a stronger T and B cell
immune reactivity in CD69-deficient mice.
CD69-deficient mice show diminished local TGF-β1 pro-
duction. A wide array of cytokines are involved in
inflammation and development of arthritis (15, 31, 32).
Since the joints are the most relevant site of cytokine
production in arthritis, we tested how CD69 deficien-
cy could affect the profile of cytokine expression in
joints of mice with CIA. RNase protection assays
showed that CD69 deficiency enhanced mRNA expres-
sion of some inflammatory mediators such as IL-1β,
RANTES, macrophage inflammatory protein–1α
(MIP-1α), and MIP-1β (Figure 4). However, the most
Figure 4
Local cytokine mRNA analysis in CII-immunized CD69–/– mice. mRNA analysis of CIA CD69+/+ (white bars) and CD69–/– (black bars) mouse
hind paws. Each lane corresponds to the mRNA pool of six mice per group, and each bar represents similar experiments (six mice per group
per experiment). Results are expressed in arbitrary densitometric units normalized for expression of the ribosomal housekeeping protein L32
in each sample (arithmetic mean ± SD of four separate experiments). *P < 0.01 versus CD69+/+ (Mann-Whitney U test). MIF, macrophage
inhibitory factor; LTβ, lymphotoxin-β; Ltn, lymphotoxin.
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significant difference was the reduction in mRNA lev-
els of the anti-inflammatory cytokines TGF-β1 and
TGF-β2 in CD69–/– mice (Figure 4). Real-time quanti-
tative RT-PCR analyses confirmed the reduction in
joint mRNA for TGF-β1 and TGF-β2 and the increase
in IL-1β and RANTES (Figure 5a).
We next determined the levels of active and total
TGF-β1 protein, directly produced by activated leuko-
cytes (33), and other cytokines in washouts of joint
tissue from CIA-challenged mice at sacrifice. In con-
trast to the unchanged systemic levels of TGF-β1
(data not shown), active and total TGF-β1 levels in the
synovial washouts were significantly reduced in
CD69-deficient mice (Figure 5b). In contrast, proin-
flammatory cytokines such as IL-1β and RANTES
were increased in synovial washouts from CD69–/–
mice as compared with WT mice, whereas TNF-α lev-
els remained locally unchanged (Figure 5b). Since
TGF-β1 is considered an anti-inflammatory cytokine
with a predominant protective role in CIA (20), these
results suggest that deficient local production of this
cytokine may account for the enhanced inflammato-
ry response observed in CD69–/– mice through the
augmented production of IL-1β and various chemo-
kines, thus altering the balance between pro- and anti-
inflammatory cytokines at synovium (15).
To ascertain the cell population responsible for the pat-
tern of cytokine expression seen in CD69–/– mice, we puri-
fied synovial cells from CIA-challenged mice. Synovial
cells were mainly CD11b+ macrophages (66.3% ± 29.4%),
with some CD3+ cells (9.6% ± 5.3%) and nonleukocyte
CD45– cells (24.1% ± 14.8%). The three subsets were iso-
lated, and quantitative RT-PCR revealed that both CD3+
and CD11b+ leukocytes contributed to the decrease in
Figure 5
Local cytokine analysis in joints and purified leukocyte synovial cells from CII-immunized CD69–/– mice. (a) Real-time quantitative RT-PCR
analysis of mRNA from CD69+/+ (white bars) and CD69–/– (black bars) mouse hind paws. Each bar represents the arithmetic mean ± SD of
12 mice per group in two independent experiments. Results for each cytokine are normalized to GAPDH expression measured in parallel in
each sample. *P < 0.01 versus CD69+/+ (Mann-Whitney U test). (b) Levels of active and total TGF-β1, IL-1β, TNF-α, and RANTES in synovial
washouts from CIA CD69+/+ (white bars) and CD69–/– (black bars) mice. Data correspond to the arithmetic mean ± SD of three independent
experiments (six mice per group per experiment). *P < 0.01 versus CD69+/+ (Mann-Whitney U test). (c) Quantitative RT-PCR analysis of mRNA
from CD69+/+ (white bars) and CD69–/– (black bars) purified subsets of synovial cells. Each histogram represents the arithmetic mean ± SD of
12 mice per group in two independent experiments. Results of each cytokine are normalized to GAPDH expression measured in parallel in each
sample. *P < 0.01 versus CD69+/+ (Mann-Whitney U test).
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TGF-β levels in CD69-deficient mice (Figure 5c). Never-
theless, the CD11b+ subset was responsible for the sub-
sequent higher proinflammatory response mediated by
IL-1β (Figure 5c), most likely playing a crucial role in the
perpetuation of synovitis.
Blockade of TGF-β increases CIA severity in WT but not in
CD69-deficient mice. The protective effects of TGF-β1 in
CIA could explain by themselves the deregulation of the
balance of some proinflammatory and chemotactic
cytokines (15, 20, 21). These results would explain the
higher infiltration of leukocytes and the inflammatory
response in joints from CD69-deficient mice. To estab-
lish a functional link between TGF-β activity and CIA
severity, a blocking anti–TGF-β antibody (28) was local-
ly injected in paws from CIA WT mice. TGF-β blockade
induced a significant increase in paw inflammation as
compared with control antibody or carrier (Figure 6a).
Joint mRNA analysis by quantitative RT-PCR showed a
significant increase in IL-1β and RANTES but not in
TNF-α and IL-18 (Figure 6a). These results indicate that
TGF-β blockade in CIA WT mice results in a similar
phenotype to that seen in CD69-deficient mice.
In contrast, local injection of anti-TGF-β in CIA
CD69–/– mice did not further enhance paw inflam-
mation (Figure 6b). Accordingly, mRNA analyses
showed no significant modification in the mRNA lev-
els for proinflammatory cytokines. These findings
reveal that TGF-β blockade and CD69 deficiency do
not cooperate to increase CIA severity, suggesting
their interdependence.
Induction of TGF-β1 production by CD69 engagement. To
analyze whether CD69 is able to regulate TGF-β1 syn-
thesis, we examined production of TGF-β1 after
CD69 engagement in ConA-activated mouse spleno-
cytes (Figure 7a). CD69 cross-linking markedly
induced total and active TGF-β1 production in vari-
ous leukocyte cell subsets (Figure 7a), concurring with
data on NK cells and anti-CD3–activated splenocytes
(13). Moreover, CD69 cross-linking triggered TGF-β1
production in infiltrating synovial cells from WT
mice with CIA, most of them CD11b+ cells bearing
CD69 (Figure 7b). In contrast, we did not detect any
differences in synthesis of TNF-α, RANTES, or IL-1β
after CD69 cross-linking (data not shown).
Το ascertain whether these results could be extended
to humans, we analyzed TGF-β1 production in CD69+
synovial mononuclear cells from patients with inflam-
matory joint diseases (Figure 8a). Cross-linked, but not
soluble, anti-CD69 induced TGF-β1 synthesis inde-
pendently of further costimulus (Figure 8a), whereas
no differences were found for other cytokines such as
TNF-α or IL-6 (data not shown). In CD69-mediated
TGF-β1 production assays, increased active TGF-β1
correlated with total TGF-β1 synthesis (Figures 7 and
8). These results demonstrate that, both in mice (Fig-
ure 7) and humans (Figure 8), there is a direct link
between CD69 engagement and TGF-β1 synthesis, and
they may explain the higher TGF-β1 levels found in
CD69+/+ mice than in CD69–/– mice.
To establish a direct connection between CD69 cross-
linking and TGF-β1 production, we took advantage of
Jurkat T cells stably transfected with human CD69 (JK-
CD69). The CD69 expressing JK-CD69 produced sig-
nificant active TGF-β after cross-linking with anti-
CD69 antibodies, in contrast with the absence of
TGF-β synthesis in the parental CD69-negative Jurkat
T cell line (Figure 8b). In addition, our data showed
that cross-linking of CD69 failed to induce TNF-α
Figure 6
Effect of a blocking anti–TGF-β antibody in WT and
CD69-deficient mice. (a) As shown in the left panel,
CD69+/+ mice were treated from day 21 (second
immunization) with the blocking anti–TGF-β anti-
body (squares), the isotype control IgG1 (triangles),
or the carrier (inverted triangles). Paw inflammation
measured with a precision caliper is expressed in mil-
limeters of inflammation with respect to day 21.
Results express the arithmetic mean ± SD of 12 mice
per group in two independent experiments. On the
right, analysis by quantitative real-time RT-PCR of
mRNA from paws treated with isotype control anti-
body (white bars) or with anti–TGF-β (black bars) is
shown. Each bar represents the arithmetic mean ± SD
of 12 mice per group in two independent experi-
ments. Results of each cytokine are normalized to
GAPDH expression measured in parallel in each sam-
ple. *P < 0.01 versus control antibody (Mann-Whit-
ney U test). (b) CD69–/– mice were treated as in a,
paw inflammation was measured (left panel), and
mRNA was determined (right panel) as above.
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production (Figure 8b). Taken together, these results
establish that CD69, a receptor expressed after activa-
tion, downregulates the autoimmune response and the
inflammatory reaction through direct secretion of
active TGF-β at inflammatory foci.
Discussion
Susceptibility to autoimmune diseases is conferred by
a variety of genetic and environmental factors. Several
autoimmune susceptibility gene clusters have been
identified in human and mouse (34, 35). Interestingly,
the CIA3 quantitative trait loci on rat chromosome 4
and murine chromosome 6, syntenic to human 12p12-
p13, contains susceptibility loci for several autoim-
mune diseases, including RA (36, 37). Since the CD69
gene is located in this region (38, 39), this receptor may
be involved in the pathogenesis of CIA. Accordingly,
the high and persistent expression of CD69 in chron-
ic inflammatory infiltrates (7, 8) suggests an impor-
tant role for this molecule in the immune reactivity
and the inflammatory reaction. CIA provides a suit-
able model for exploring CD69 function in the devel-
opment and perpetuation of chronic inflammatory
conditions. Here, we provide evidence that CD69 has
an inhibitory role in CIA pathogenesis. Under specific
conditions that generate a moderate CIA in B6 WT
mice (24, 32), CD69-deficient mice develop an exacer-
bated form of CIA. This condition correlates with a
higher immune reactivity characterized by an enlarged
spleen with increased cellularity and enhanced CII-spe-
cific T and B cell responses. This altered immune reac-
tivity observed in CD69–/– mice leads to the synthesis
of Th1-dependent anti-CII antibodies (IgG2c, IgG2b)
involved in the pathogenesis of CIA (40).
Our data show a significant reduction in TGF-β1
expression in joints from CD69–/– mice, accompanied
by an increase in some inflammatory mediators, such
as IL-1β, RANTES, MIP-1α, and MIP-1β. However, no
significant enhancement in TNF-α was observed.
Although this cytokine is an important mediator of
inflammation in arthritis (41), our results indicate
that there are alternative pathways of inflammation in
which TNF-α does not have a predominant role. Our
data are in agreement with previous reports showing
that TNF-α is not essential to the development of
arthritis (42, 43), since there is severe inflammatory
arthritis in the absence of TNF-α (32). In these arthri-
tis mouse models, IL-1β exerted a key role in mediat-
ing inflammation. Similarly, in humans, TNF-α ther-
apy alone or with concomitant methotrexate is
effective in no more than 40% of patients with RA at
30 weeks of treatment (American College of Rheuma-
tology 50% improvement criteria) (44, 45), and IL-1β
inhibitors have a moderate effect (46). These results
suggest the importance of the balance between pro-
and anti-inflammatory cytokines, which is not
dependent on a single cytokine (15). Disruption of the
tightly controlled cytokine network by TGF-β1 down-
Figure 7
CD69 engagement induces TGF-β1 secretion in mouse splenocytes and synovial leukocytes from CIA mice. (a) ConA-stimulated splenocytes
were stained for CD69 (solid line, left panel) and an isotype-matched antibody (dotted line, left panel). Activated splenocytes were then
purified in different subsets and treated with an anti-mouse CD69 (black bars) or an isotype-matched control antibody (white bars), and a
cross-linking secondary antibody was added. Active and total TGF-β1 were determined (right panel). (b) Mouse synovial cells from CIA mice
were stained for CD11b and CD69 (middle panel) or isotype control antibodies (left panel). Synovial cells were treated as in a, and active
and total TGF-β1 was determined (right panel). Results in a and b are expressed as the arithmetic mean ± SD of four independent experi-
ments. *P < 0.01 versus control antibody (Mann-Whitney U test). XL, cross-linker.
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regulation results in enhanced immune reactivity and
induction of autoimmunity (15, 19, 23). Our findings
reveal that local TGF-β blockade leads to enhanced
CIA and increased expression of IL-1β and RANTES in
WT mice, establishing a direct link between TGF-β
downregulation and increased paw inflammation.
Moreover, TGF-β blockade does not increase CIA
severity in CD69-deficient mice, suggesting the inter-
dependence of both processes and the importance of
the balance of TGF-β levels in the final outcome of
inflammation. Our results are in agreement with pre-
vious reports showing that TGF-β1 has a protective
role against the immune response that mediates CIA
(20) and other inflammatory processes (23), such as
experimental allergic encephalomyelitis (47), colitis (48),
and autoimmune diabetes (49). In addition, TGF-β1
null mice develop a lethal autoimmune-like process
(16, 17), and the abrogation of TGF-β signaling in T
cells leads to autoimmune disease (50). Finally, previ-
ous results in B cells defective for TGF-β–mediated sig-
naling (51) concur with our data on high levels of anti-
CII IgG3 antibodies in CD69–/– mice, which reveal B
cell hyperresponsiveness.
Our in vivo results show that CD69 exerts an inhibito-
ry effect on CIA and strongly suggest that this molecule
functions as a negative regulator of the immune
response and the inflammatory reaction. This is in
accordance with the role of CD69 in NK cell–mediated
tumor rejection (13). The induction of TGF-β1 synthe-
sis after CD69 engagement establishes a possible mech-
anism through which CD69 regulates the autoimmune
response. Previous in vitro results showed that soluble
anti-CD69 antibodies enhanced the T cell proliferation
induced by suboptimal doses of PMA (3). However, other
anti-CD69 antibodies inhibited IL-1–dependent T cell
proliferation (2). Similar opposing effects have been
reported for cytoxic T-lymphocyte–associated antigen-4
(CTLA-4), a receptor that has a clear-cut negative regu-
latory effect on the immune response in vivo.
Anti–CTLA-4 antibodies promote T cell proliferation in
soluble form, yet they actively block lymphocyte prolif-
eration and induce TGF-β1 production when cross-
linked (52, 53). Moreover, our data show that CD69
cross-linking without further costimulation promotes
TGF-β1 but not TNF-α synthesis. The reported effect of
anti-CD69 on TNF-α production in vitro required the
presence of phorbol esters (30, 54). Moreover, CD69
engagement in CD69-transfected Jurkat T cells mediat-
ed TGF-β production but not TNF-α synthesis. In addi-
tion, it has been suggested that CD69 putative ligand(s)
would mediate TNF-α synthesis through the interaction
with CD69 (55). Therefore, although our results demon-
strate that CD69 acts as a negative regulatory receptor in
vivo, this molecule may have a complex role in TNF-α
production that would be redundant in CD69-deficient
mice (e.g., the putative ligand could be shared with
Figure 8
CD69 cross-linking induces TGF-β1 production in human synovial leukocytes and in a human CD69 T cell stable transfectant. (a) Human
synovial leukocytes from patients with RA were stained for CD69 (solid line, left panel) and isotype-matched antibody (dotted line, left
panel). Synovial leukocytes were treated with anti-human CD69 (black bars) or an isotype-matched control antibody (white bars) in the
presence (XL) or absence (–) of a cross-linking secondary antibody, and active and total TGF-β1 were determined (right). *P < 0.01 versus
control antibody (Mann-Whitney U test). These results are representative of similar data obtained on synovial leukocytes from patients with
reactive arthritis or ankylosing spondylitis. (b) Jurkat human T cell leukemic cell line (dotted line, left panel) and CD69 stable transfectants
(solid line, left panel) were stained for CD69. Production of TGF-β1 but not TNF-α by CD69 engagement is shown in the right panel. The
human T lymphoblastoid cell line Jurkat (JK) (white bars) and the stable transfectant expressing CD69 (JK-CD69) (black bars) were treated
for 24 hours with cross-linked anti-CD69. Results in a and b are expressed as the arithmetic mean ± SD of four independent experiments.
*P < 0.01 versus the parental JK cell line (Mann Whitney U test).
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another molecule) and would suggest a very fine tuning
of pro- and anti-inflammatory cytokines (15).
It is evident that the involvement of CD69 in TGF-β1
synthesis would be restricted to the leukocyte subsets
expressing this molecule in chronic inflammation —
namely, infiltrating T cells and macrophages. A signif-
icant fraction of RA synovial leukocytes persistently
express CD69 (7), and these cells are partially hypore-
sponsive (56). TGF-β1, which is present in the synovi-
um (57), would inhibit the immune response (58), and
CD69 may play an important role in TGF-β1–mediat-
ed immunosuppression in vivo. Our data show that
CD69-bearing human synovial mononuclear cells
from inflamed joints secrete active TGF-β1 after CD69
cross-linking without further costimulus. It is thus
feasible that in vivo the interaction of CD69 with its
putative ligand(s) leads to TGF-β1 production and
attenuation of the immune/inflammatory response.
Serum IgG anti-CD69 autoantibodies have been
detected in a proportion of patients with RA, correlat-
ing with disease severity (59). We could hypothesize
that these autoantibodies block the interaction of
CD69 with its ligand, reducing TGF-β1 production
and resulting in a more severe disease. In addition, any
defect in the expression or molecular alteration of the
putative CD69 ligand may also result in deficient
TGF-β1 synthesis. On the other hand, agonistic anti-
CD69 antibodies, which would induce local TGF-β1
secretion, may represent a novel approach for the ther-
apy of chronic inflammation, avoiding the detrimen-
tal effects of systemic TGF-β1 upregulation (23).
Our results support a novel role for CD69 as a mole-
cule induced early after lymphocyte activation that trig-
gers an inhibitory feedback loop mediated through
TGF-β1 production to control the immune reactivity
and the inflammatory phenomenon. Given the highly
pleiotropic nature of TGF-β1, its synthesis driven
through CD69 could restrict its activity to local anti-
genic stimulation sites, where it may play an important
role in the suppression of autoimmune diseases. Fur-
ther work is necessary to determine whether agonist
anti-CD69 or the unknown ligand could be used effec-
tively as therapeutic tools to dampen the immune
response specifically at inflammatory foci.
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